Clearmind Medicine Welcomes President Trump’s Executive Order as a Historic Catalyst for Psychedelic Innovation and Veteran Mental Health Care
Clearmind Medicine Inc. - Common Shares (CMND)
NASDAQ:AMEX Investor Relations:
ir.manitowocfoodservice.com/investor-relations/default.aspx
Company Research
Source: GlobeNewswire
Vancouver, Canada, April 20, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage psychedelic biotech company focused on the discovery and development of novel, non-hallucinogenic, neuroplastogen-derived therapeutics to solve major under-treated health problems, today commended President Donald J. Trump’s Executive Order signed on April 18, 2026, titled Accelerating Medical Treatments for Serious Mental Illness, which directs the U.S. Food and Drug Administration (FDA) to prioritize review processes for certain psychedelic drugs designated as breakthrough therapies and expands patient access pathways. “We are pleased to see psychedelic medicines, including non-hallucinogenic neuroplastogens, gaining increasing mainstream recognition and regulatory momentum as promising solutions for serious mental health conditions,” said Dr. Adi Zuloff-Shani, Ph.D., Chief Executive Officer of Clearmind Medicine. “This Executive Order hig
Show less
Read more
Impact Snapshot
Event Time:
CMND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CMND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CMND alerts
High impacting Clearmind Medicine Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
CMND
News
- Clearmind Medicine Announced Positive Top-Line Safety Results: CMND-100 Proprietary Psychedelic Treatment Meets Primary Endpoint in AUD TrialGlobeNewswire
- Clearmind Medicine Announces Positive Data Safety Monitoring Board Recommendation in ongoing CMND-100 clinical trialGlobeNewswire
- Clearmind Medicine’s CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use DisorderGlobeNewswire
- Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder [Yahoo! Finance]Yahoo! Finance
- Clearmind Medicine Announces Successful Completion of Treatment and Follow-up for 18 Participants in its Ongoing Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use DisorderGlobeNewswire
CMND
Sec Filings
- 4/21/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- CMND's page on the SEC website